NASDAQ$CMPX
Compass Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Compass Therapeutics reported Q3 2025, net loss of $14.3M.
For Q3 2025, Compass Therapeutics reported a net loss of $14.3M. Management discusses segment performance, capital allocation, and sector risks in the quarterly filing.
- Net loss $14.3M.
- Compass Therapeutics MD&A covers liquidity, credit, and operating priorities.
- Compass Therapeutics MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Compass · Revenue · Quarterly
$850K
Forward guidance
Clinical-stage biotech outlook centers on trial milestones, partnerships, and cash runway.
Tailwinds
- Pipeline milestones and collaboration optionality.
- Cash funds operations.
Headwinds
- Trial delay or failure risk.
- Future financing dilution.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2025
-1.9%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-1.4%
Avg return
30 days after
47%
9 / 19 earnings
Positive
+10.3%
Q1 2023
Best reaction
-17.6%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.0% | -2.1% | -4.2% | |
| Q3 2025 | +1.1% | +12.9% | +45.9% | |
| Q1 2025 | +4.0% | +2.0% | +19.3% | |
| Q4 2024 | -1.7% | -6.4% | -33.0% | |
| Q3 2024 | -11.1% | -27.4% | -20.5% | |
| Q2 2024 | +10.1% | +6.4% | +37.6% | |
| Q1 2024 | +1.3% | +0.0% | -25.0% | |
| Q4 2023 | +0.5% | -6.6% | -30.7% | |
| Q3 2023 | -9.9% | -11.0% | +1.2% | |
| Q2 2023 | -3.8% | -5.3% | -9.2% | |
| Q1 2023 | +10.3% | +13.3% | -1.8% | |
| Q4 2022 | -5.0% | -10.8% | -13.9% | |
| Q3 2022 | -4.0% | +10.4% | +1.4% | |
| Q2 2022 | +1.2% | +2.3% | +5.8% | |
| Q1 2022 | -3.0% | +50.3% | +63.9% | |
| Q4 2021 | +6.2% | +4.6% | +20.8% | |
| Q3 2021 | +0.3% | +7.2% | -16.2% | |
| Q2 2021 | -11.9% | -6.0% | -16.7% | |
| Q1 2021 | -17.6% | -17.6% | -50.6% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro